S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.

S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.

BACKGROUND: Deregulation of the phosphatidylinositol 3-kinases (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway plays a central role in tumor formation and progression, providing validated targets for cancer therapy. S9, a hybrid of alpha-methylene-gamma-lactone and 2-phenyl indole compound,...

Full description

Bibliographic Details
Main Authors: Chao Zhang, Na Yang, Chun-Hao Yang, Hua-Sheng Ding, Cheng Luo, Yu Zhang, Mao-Jiang Wu, Xiong-Wen Zhang, Xu Shen, Hua-Liang Jiang, Ling-Hua Meng, Jian Ding
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2654064?pdf=render

Similar Items

Similar Items